Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of glucose-lowering drugs, including canagliflozin, dapagliflozin, and empagliflozin, that block the SGLT2 protein located in the proximal convoluted tubule of the nephron for adults with type 2 diabetes [13]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.